Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma.
Malouf
G G
GG
Department of Medicine.
Duclos
J
J
Department of Pathology.
Rey
A
A
Department of Biostatistics.
Duvillard
P
P
Department of Pathology.
Lazar
V
V
Department of Platform of Genomics.
Haie-Meder
C
C
Department of Radiotherapy.
Balleyguier
C
C
Department of Radiology.
Morice
P
P
Department of Surgery, Institut Gustave-Roussy, Villejuif, France.
Lhommé
C
C
Department of Medicine.
Pautier
P
P
Department of Medicine. Electronic address: pautier@igr.fr.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D010386:Pelvic Neoplasms / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018203:Sarcoma, Endometrial Stromal / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate